Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer (NCT00176254), a na phase 2 study. The primary outcome is Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation).

2. Clinical Question

This is a question about response after an initial treatment sequence, not a randomized comparison of alternative induction approaches. The record’s brief summary frames radiation as a possible chemoenhancer and says the study evaluates whether it increases the initial response rate. Without a comparator arm or posted response results, that motivation should not be read as evidence that an increase occurred. The listed secondary outcomes concern severe toxicity and survival measures, but their outcome values are not reported in the registry record.

3. Trial Design

The registry record identifies NCT00176254 as a phase 2, completed, single-group study. It lists an enrollment of 40 and one arm, titled “Induction chemotherapy and radiation.” The arm description characterizes the treatment as induction chemotherapy with low-dose radiation. Allocation is marked not applicable and masking is listed as none. These design details mean the record does not describe random assignment or a blinded comparison.

The brief summary describes two cycles of paclitaxel and carboplatin followed by four small doses of radiation, before other treatment such as surgery or radiation. The primary outcome is response to induction chemotherapy before definitive therapy. The timeframe is assessment before study treatment and one assessment between days 36-57. The record does not give detailed dose levels, administration schedules, or rules for selecting subsequent definitive treatment.

The listed start date is 2000-05 and the primary completion date is 2012-10. The status is completed. These registry dates do not, by themselves, establish when all outcomes were measured or when results were analyzed. The registry record names Susanne Arnold as sponsor.

Because this is a single-group design, its observed outcomes could describe what happened among participants treated in the study, but the design does not by itself isolate the effect of radiotherapy from the chemotherapy or other aspects of care. It also cannot provide a direct randomized estimate against another regimen. The registry record does not report a protocol-level statistical plan, a sample-size justification, or details of enrollment and follow-up beyond the outcome timeframes it lists.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation), measured over assessed pre-study and once between days 36-57.

The primary endpoint is the response rate to induction chemotherapy before definitive therapy, which the record describes as surgery or radiation. It uses MRI assessment of target lesions and RECIST v1.0 criteria. A complete response means disappearance of all target lesions. A partial response means a decrease of at least 30% in the sum of the longest diameters of target lesions. Overall response combines complete and partial responses.

A response endpoint can capture whether measurable target lesions have changed after an initial treatment course. It is a short-term measure of tumor response, distinct from longer-term outcomes such as overall survival, disease-specific survival, or progression-free survival. The registry lists those survival outcomes as secondary measures, alongside severe toxicities.

The assessment is described as occurring before study treatment and once between days 36-57. The record does not specify the response-evaluation denominator, report the counts in each response category, or provide a numerical response rate. It also does not report how missing or unevaluable MRI assessments were handled. Thus the endpoint definition is available, but the posted registry information does not establish the observed response result or its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

General statistical context: a binary response endpoint classifies each evaluable assessment into response or no response, according to the prespecified response definition. A response proportion is ordinarily interpreted together with its denominator and a measure of uncertainty. The registry record defines the response categories, but does not report the response count, analysis denominator, or a confidence interval. No response proportion should therefore be inferred from the planned enrollment alone.

What does the response definition contribute?

RECIST v1.0 makes the imaging endpoint more explicit by defining complete response as disappearance of all target lesions and partial response as a decrease of at least 30% in the sum of the longest diameters of target lesions. Combining complete and partial response into overall response creates a binary outcome for the primary question. This standardization helps specify what qualifies as a response; it does not by itself establish whether imaging assessments were complete, consistently performed, or independently reviewed. Those operational details are not reported in the registry record.

The described timing includes an assessment before study treatment and one between days 36-57. In general, a fixed assessment window helps define when an outcome is measured. Interpretation still depends on how participants without an assessment in that window are handled and whether all assessments follow the same rules. Missing-assessment handling is not reported in the registry record, so it is not possible to determine whether an analysis used all enrolled participants, only those with evaluable imaging, or another population.

Why does the single-group design matter?

In general, a single-group study can describe the outcomes observed under its treatment regimen. It lacks a concurrent randomized control group, so differences from outcomes in other settings cannot be attributed to the regimen using the trial comparison alone. Participant selection, disease severity, assessment practices, supportive care, and other features can differ across studies. This is especially relevant when a study’s motivation is to ask whether one component enhances another: the design must support a comparison that separates the component effects to answer that question causally. The registry lists a single group and no randomized comparator.

The record does not report an inferential test, a regression model, covariate adjustment, or a prespecified statistical plan. No such approach should be assumed. General methods for binary outcomes may include estimation of a proportion and its interval, but the method used for this trial is not reported. With no reported outcome count or analysis, recalculating a simple unadjusted estimate is not possible from the registry information.

How should planning illustrations be understood?

The stated planning assumptions describe an illustration based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustration is not a description of the actual trial design: the registry identifies this trial as single-group. A calculation under equal allocation between two arms is therefore a hypothetical planning exercise, not an analysis of the enrolled study groups. The record also says that the effect to detect is a stated fraction of the observed effect; the numerical effect and the resulting planning estimates are not reported in the registry record for this record.

In general, a sample-size calculation asks how much information a proposed design would need to detect a specified effect under stated assumptions. It is not a measure of the probability that a completed study’s result is true. In particular, sample-size planning illustrations should not be described as observed power. The record’s planning language explicitly characterizes the exercise as an illustration rather than the trial’s own design justification. No protocol sample-size justification is reported in the registry record.

What do uncertainty and multiplicity mean in general?

A confidence interval communicates the precision of an estimated quantity under its assumptions; a wider interval indicates less precision than a narrower one. A p-value, when used, describes how unusual data at least as incompatible with a specified null model would be if that model held. Neither quantity establishes clinical importance on its own, and neither is a substitute for the estimated response and its uncertainty. The registry record does not report a confidence interval or p-value for the primary endpoint.

Multiplicity arises when several outcomes or comparisons are tested, because repeated testing can increase the chance of at least one apparently unusual result. Here, the record lists one primary response outcome and several secondary outcomes, including toxicity and survival outcomes. It does not report whether multiplicity adjustments, a testing hierarchy, or any other strategy were prespecified. The number of outcome measures listed is not evidence that each was tested or that a particular adjustment was used.

Finally, binary outcomes count events rather than measuring a continuously varying quantity. General statistical methods for such data rely on defining the event, the analysis population, and the observation period. The endpoint description supplies the response definition and assessment window, but the registry record does not provide the participant-level analysis rules, handling of missing assessments, or analysis results needed to assess those choices.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Treatment Arm: Induction LDFRT and Chemotherapy")
n      <- c(39)
events <- c(32)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Treatment Arm: Induction LDFRT and Chemotherapy  39  32  82.1  66.5  92.5  67.3  91.0  67.2  90.9

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists a primary response outcome and secondary outcomes for severe toxicities, overall survival, disease-specific survival, and progression-free survival. It does not report a multiplicity strategy, such as adjustment for testing multiple outcomes, a hierarchy of tests, or a distinction between confirmatory and exploratory analyses. The presence of several outcomes does not establish that statistical tests were performed for each.

Missing-data handling is not reported in the registry record. In particular, the record does not say how participants without a post-treatment MRI, with an assessment outside the stated window, or with unevaluable target lesions would be handled in the response analysis. It does not report imputation, sensitivity analyses, or rules for determining the analysis denominator. Planned enrollment should not be assumed to equal the number included in any outcome analysis.

The analysis populations are also not reported. The registry does not specify whether analyses were based on all enrolled participants, those who began treatment, those who completed the induction regimen, or those with evaluable outcome data. No interim-analysis plan or statistical analysis plan is reported. The record lists zero analyses, so it offers no posted inferential results with which to assess these decisions.

These omissions matter because definitions for missing outcomes, analysis populations, and multiplicity can affect how an estimate is interpreted. Without the corresponding methods and outcome results, the registry record supports a description of the intended outcome measures, not a reconstruction of the analysis.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutropenia (37.5%), infection/fever (2.5%).

The registry’s treatment-arm safety entry lists 40 at risk for serious adverse events and 16 recorded with a serious event. Its other-adverse-event entry lists 40 at risk and 35 affected. These are the recorded counts; the registry information does not establish whether the categories overlap or whether an individual could contribute more than one event. The counts should not be added together.

The top serious-event terms are listed as neutropenia at 37.5% and infection/fever at 2.5%. The record does not give the detailed term-specific counts, event timing, severity breakdown for each term, or the calculation denominator in the registry record for these entries. The term percentages should therefore be read as registry-reported values, not independently reconstructed rates.

Serious adverse events and severe toxicities are not interchangeable labels. The registry lists severe toxicities, defined as Grade 3 or higher, as a secondary outcome, while the adverse-event entry separately reports serious events and other events. The record does not provide a complete toxicity analysis or a comparison group. These figures describe recorded safety entries and should not be interpreted as a comparative estimate of risk.

13. What the Result Does, and Does Not, Mean

The record establishes that the study was designed to examine MRI-based response after induction chemotherapy and low-dose radiotherapy, before definitive therapy. It defines overall response as complete response or partial response under RECIST v1.0. It also identifies toxicity and survival as secondary outcomes. These details clarify what investigators intended to measure.

The registry record does not report the primary response count or rate, a confidence interval, or an analysis result. It therefore does not establish the magnitude or precision of response in the study. The record’s rationale about radiation as a chemoenhancer is not a result, and the single-group design does not provide a randomized contrast that could show whether adding radiation changed response relative to an alternative regimen.

The study also cannot be interpreted from the listed adverse-event figures as a comparison of safety between treatments. The safety entry describes one treatment arm, and the registry does not report a control arm. Serious events, other adverse events, and severe toxicities refer to different recorded categories; the registry entries do not justify treating them as interchangeable or combining their counts.

More broadly, response before definitive treatment is not the same outcome as long-term survival. The registry names 5 Year Overall Survival Rates, 5 Year Disease-specific Survival, and 5 Year Progression Free Survival as secondary outcomes, but does not report their results. No conclusion about those outcomes follows from the endpoint definitions or the study status alone.

The most defensible reading is descriptive: the registry records a completed phase 2 single-group study, outlines its treatment sequence and endpoints, and includes limited adverse-event entries. It does not provide the outcome analyses needed to judge the observed response or survival results, their uncertainty, or a causal treatment effect.

14. Why This Trial Matters Statistically

This trial illustrates why a clearly defined endpoint and an interpretable design are separate parts of statistical evidence. The response endpoint is specified using MRI and RECIST v1.0, including definitions for complete and partial response. That detail clarifies the intended measurement. It cannot compensate for the absence of a posted response result, denominator, or uncertainty estimate.

The single-group structure also highlights the difference between describing outcomes and estimating comparative effects. A study may record what happened after a treatment sequence, but without a concurrent comparator it cannot directly estimate how outcomes differ under another regimen. That distinction is particularly relevant to a study rationale framed around whether one treatment component enhances another.

The record also offers a practical example of why planning estimates need careful labeling. Its planning assumptions describe an equal-allocation two-arm illustration, whereas the recorded trial design is single-group. A hypothetical calculation does not change the actual design, establish an observed effect, or provide observed power. Nor does the record state that this illustration was the study’s original sample-size justification.

Finally, the listed primary and secondary outcomes raise questions about analysis populations, missing data, and multiplicity. Those choices influence the meaning of estimates, but they are not reported in the registry record. Statistical interpretation depends not only on endpoint definitions, but also on transparent reporting of results and the methods used to produce them.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the available registry record is that it does not report the primary response result or any analysis. Although the outcome definition and assessment timeframe are described, response counts, the analysis denominator, and measures of uncertainty are not reported. The completed status does not fill those gaps.

The single-group design has no recorded concurrent comparator. It can describe outcomes under the induction regimen, but cannot by itself separate the effects of paclitaxel, carboplatin, and radiotherapy or establish a causal difference from another treatment. The record’s research rationale should not be mistaken for a comparative result.

Details needed to assess outcome ascertainment are limited. The record names MRI and RECIST v1.0 and gives the assessment window, but does not report reviewer procedures, missing-imaging rules, or the handling of participants without an evaluable response. Analysis populations, protocol deviations, and the statistical analysis plan are not reported.

The registry lists secondary toxicity and survival outcomes but does not provide their results. It also does not report a multiplicity approach, interim-analysis plan, or a protocol-level sample-size justification. The planning assumptions describe an illustration using a two-arm setup that differs from the single-group design; the numerical planning results are not available in the registry entries.

Safety entries are limited to the listed at-risk and affected counts and top serious-event terms. The record does not provide enough information to determine category overlap, event timing, or a comparative safety estimate. These limitations constrain interpretation of both efficacy and safety.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer — NCT00176254.
• Registry record last updated 2023-05-16; status last verified 2023-04.
• Results first posted 2014-01-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00176254 is listed as a completed phase 2, single-group study with planned enrollment of 40. It concerns squamous cell carcinoma and describes induction chemotherapy with paclitaxel and carboplatin followed by low-dose radiotherapy, before definitive treatment. The primary outcome is MRI-assessed response before definitive therapy, defined using RECIST v1.0. The record lists severe toxicity and survival measures as secondary outcomes.

The registry describes the treatment and endpoint but does not report the primary response result, survival outcomes, or a statistical analysis. It lists one treatment arm and no comparator. Limited safety entries include serious and other adverse-event counts and the top serious-event terms. The information supports a description of the intended study and recorded safety entries, but not a conclusion about treatment effects or comparative outcomes.